Ensysce Biosciences Inc (ENSC)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 09-2025 | 06-2025 | 03-2025 | 12-2024 | 09-2024 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -7,408 | -3,679 | -1,946 | -7,987 | -4,423 |
| Depreciation Amortization | N/A | N/A | N/A | 1,197 | 1,197 |
| Accounts payable and accrued liabilities | -894 | -314 | -742 | -579 | -58 |
| Other Working Capital | 722 | -1,042 | 183 | -851 | -3,604 |
| Other Operating Activity | 1,299 | 621 | 797 | 717 | 148 |
| Operating Cash Flow | $-6,281 | $-4,414 | $-1,707 | $-7,503 | $-6,739 |
| Cash Flows From Investing Activities | |||||
| Purchase Of Investment | -124 | N/A | N/A | N/A | N/A |
| Investing Cash Flow | $-124 | $N/A | $N/A | $N/A | $N/A |
| Cash Flows From Financing Activities | |||||
| Debt Repayment | N/A | N/A | N/A | -485 | -485 |
| Common Stock Issued | 5,188 | 3,691 | 1,448 | 12,207 | 11,849 |
| Other Financing Activity | -613 | -567 | -190 | -1,841 | -1,595 |
| Financing Cash Flow | $4,575 | $3,124 | $1,258 | $9,881 | $9,769 |
| Beginning Cash Position | 3,502 | 3,502 | 3,502 | 1,124 | 1,124 |
| End Cash Position | 1,673 | 2,212 | 3,053 | 3,502 | 4,154 |
| Net Cash Flow | $-1,829 | $-1,291 | $-450 | $2,379 | $3,030 |
| Free Cash Flow | |||||
| Operating Cash Flow | -6,281 | -4,414 | -1,707 | -7,503 | -6,739 |
| Free Cash Flow | -6,281 | -4,414 | -1,707 | -7,503 | -6,739 |